Applied Therapeutics

OverviewSuggest Edit

Applied Therapeutics is a clinical-stage biopharmaceutical company developing therapies for diabetic complications. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) that is being developed for the treatment of diabetic cardiomyopathy, or DbCM, fatal fibrosis of the heart. The company is also developing AT-007, a central nervous system penetrant ARI, for the treatment of galactosemia.

TypePublic
Founded2017
HQNew York, US
Websiteappliedtherapeutics.com

Latest Updates

Employees (est.) (May 2019)4
Job Openings4
Share Price (Apr 2020)$31 (+6%)

Key People/Management at Applied Therapeutics

Shoshana Shendelman

Shoshana Shendelman

CEO & Founder
Mark Vignola

Mark Vignola

Chief Financial Officer
Riccardo Perfetti

Riccardo Perfetti

Chief Medical Officer
Show more

Applied Therapeutics Office Locations

Applied Therapeutics has an office in New York
New York, US (HQ)
545 5th Ave #1400
Show all (1)

Applied Therapeutics Financials and Metrics

Applied Therapeutics Revenue

USD

Net income (FY, 2019)

(45.5m)

EBIT (FY, 2019)

(45.6m)

Market capitalization (2-Apr-2020)

144.4m

Closing stock price (2-Apr-2020)

31.0

Cash (31-Dec-2019)

18.9m

EV

127.6m
Applied Therapeutics's current market capitalization is $144.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

582.0k2.0m13.2m

R&D expense

3.7m11.5m32.4m

Operating expense total

4.3m13.5m45.6m

EBIT

(4.3m)(13.5m)(45.6m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019

General and administrative expense

1.9m4.2m3.3m

R&D expense

6.9m4.3m7.5m

Operating expense total

8.7m8.4m10.7m

EBIT

(8.7m)(8.4m)(10.7m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

3.3m18.7m18.9m

Prepaid Expenses

9.0k1.5m7.3m

Current Assets

3.3m20.2m46.2m

Total Assets

3.3m20.2m48.4m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019

Cash

14.7m41.1m13.1m

Prepaid Expenses

2.2m5.7m4.1m

Current Assets

16.9m46.8m37.0m

Total Assets

16.9m46.8m37.3m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(4.3m)(16.5m)(45.5m)

Accounts Payable

5.8m

Cash From Operating Activities

(3.2m)(11.2m)(36.3m)

Cash From Investing Activities

(20.0m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019

Net Income

(8.7m)(17.2m)(27.9m)

Accounts Payable

(366.0k)462.0k(1.3m)

Cash From Operating Activities

(7.0m)(16.1m)(23.9m)

Cash From Investing Activities

(19.9m)
USDY, 2019

EV/EBIT

-2.8 x

EV/CFO

-3.5 x

Financial Leverage

1.5 x
Show all financial metrics

Applied Therapeutics Operating Metrics

Q1, 2019

Phase II Patients Enrolled

120
Show all operating metrics

Applied Therapeutics Online and Social Media Presence

Embed Graph

Applied Therapeutics News and Updates

Applied Therapeutics Reports Fourth Quarter and Year-end 2019 Financial Results

NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the …

Applied Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering of 2,741,489 Shares of Common Stock

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricin…

Applied Therapeutics Reports Third Quarter 2019 Financial Results

NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2019.

Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting

NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentation of data at the…

Applied Therapeutics Reports Second Quarter 2019 Financial Results

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2019.

Applied Therapeutics Reports First Quarter 2019 Financial Results

-Strengthened Financial Position with Recent Initial Public Offering-

Applied Therapeutics Blogs

Applied Therapeutics to Present at the Barclays Global Healthcare Conference

NEW YORK , March 10, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at

Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer

Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer Content Import Tue, 03/03/2020 - 07:01 Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer March 3, 2020 at 7:00 AM EST This release is a backfill from a News Wire …

Applied Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

Applied Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference Content Import Wed, 02/26/2020 - 16:06 Applied Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference February 26, 2020 at 4:05 PM EST This…

Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares of Common Stock

Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares of Common Stock Content Import Tue, 01/28/2020 - 12:24 Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the …

Applied Therapeutics, Inc. Announces Offering of 1,750,000 Shares of Common Stock

NEW YORK , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it

Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients

AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p
Show more

Applied Therapeutics Frequently Asked Questions

  • When was Applied Therapeutics founded?

    Applied Therapeutics was founded in 2017.

  • Who are Applied Therapeutics key executives?

    Applied Therapeutics's key executives are Shoshana Shendelman, Mark Vignola and Riccardo Perfetti.

  • How many employees does Applied Therapeutics have?

    Applied Therapeutics has 4 employees.

  • Who are Applied Therapeutics competitors?

    Competitors of Applied Therapeutics include Sensulin, glyscend and Pila Pharma.

  • Where is Applied Therapeutics headquarters?

    Applied Therapeutics headquarters is located at 545 5th Ave #1400, New York.

  • Where are Applied Therapeutics offices?

    Applied Therapeutics has an office in New York.

  • How many offices does Applied Therapeutics have?

    Applied Therapeutics has 1 office.